Extended-spectrum β-lactamase-producing enterobacteriaceae: In vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline

Medical Principles and Practice

Volumn 21, Issue 6, 2012, Pages 543-547

  Al Zarouni, M ^a   Senok, A ^c   Al Zarooni, N ^a   Al Nassay, F ^a   Panigrahi, D ^b  

^a Al Qassimi Hospital   (United Arab Emirates)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

^c ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Extended spectrum lactamase; Fosfomycin; Hyplex; Tigecycline; Uropathogens

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; CONTROLLED STUDY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PROTEUS MIRABILIS; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; BETA-LACTAM RESISTANCE; CHI-SQUARE DISTRIBUTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FOSFOMYCIN; GENOTYPE; HUMANS; MINOCYCLINE; NITROFURANTOIN; UNITED ARAB EMIRATES; URINARY TRACT INFECTIONS;

EID: 84867576660     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000339200     Document Type: Article

References (17)

1. Paterson DL, Bonomo RA: Extended-spec-trum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
2. Livermore DM, Hawkey PM: CTX-M: changing the face of ESBLs in the UK. J An-timicrob Chemother 2005; 56: 451-454.
3. Pitout JD, Laupland KB: Extended-spectrum beta-lactamase-producing Enterobacteria-ceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159-166.
4. Nordmann P, Poirel L, Toleman MA, Walsh TR: Does broad-spectrum beta-lactam resis-tance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimi-crob Chemother 2011; 66:689-692.
5. Al-Zarouni M, Senok A, Rashid F, Al-Jesmi SM, Panigrahi D: Prevalence and antimicro-bial susceptibility pattern of extended-spec-trum beta-lactamase-producing Enterobac-teriacea e in the United Arab Emirates. Med Princ Pract 2008; 17:32-36.
6. Garau J: Other antimicrobials of interest in the era of extended-spectrum beta-lac-tamases: fosfomycin, nitrofurantoin and ti-gecycline. Clin Microbiol Infect Dis 2008; 14(suppl 1):198-202.
7. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N: What re-mains against carbapenem-resistant Entero-bacteriaceae? Evaluation of chlorampheni-col, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-419.
8. De Cueto M, Hernandez JR, Lopez-Cerero L, Morillo C, Pascual A: Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Enferm Infecc Microbiol Clin 2006; 24:613-616.
9. Biondo CM, Rocha JL, Tuon FF: Fosfomycin in vitro resistance of Escherichia coli from the community. Braz J Infect Dis 2011; 15:96.
10. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA, Hoban DJ: Antibiotic resistance in Esch-erichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006; 27:468-475.
11. Fadda G, Nicoletti G, Schito GC, Tempera G: Antimicrobial susceptibility patterns of con-temporary pathogens from uncomplicated urinary tract infections isolated in a multi-center Italian survey: possible impact on guidelines. J Chemother 2005; 17:251-257.
12. Al Benwan K, Al Sweih N, Rotimi VO: Etiol-ogy and antibiotic susceptibility patterns of community-and hospital-acquired urinary tract infections in a general hospital in Ku-wait. Med Princ Pract 2010; 19: 440-446.
13. Bindayna K, Senok A, Jamsheer A: Extended Spectrum Beta-lactamase- producing En-terobacteriaceae in Bahrain: Prevalence and antibiotic sensitivity pattern. J Infect Public Health 2009; 2:129-135.
14. Khanfar HS, Bindayna KM, Senok AC, Botta GA: Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and com-munity settings. J Infect Dev Ctries 2009; 3: 295-299.
15. Alfaresi MS, Elkoush AA, Alshehhi HM, Ab-dulsalam AI: Molecular characterization and epidemiology of extended-spectrum be-ta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in the United Arab Emirates. Med Princ Pract 2011; 20: 177-180.
16. CTX-M genes car-ried by clinically significant Escherichia coli isolates in Kuwait hospitals. Med Princ Pract 2011; 20: 213-219.
17. Al-Agamy MH, Shibl AM, Tawfik AF: Preva-lence and molecular characterization of ex-tended-spectrum beta-lactamase-producing Klebsiella pneumoniae in Riyadh, Saudi Ara-bia. Ann Saudi Med 2009; 29:253-257.